Pharmaceutical Executive-04-01-2015

Pharmaceutical Executive

Expert panel on rare disease highlights the challenges of serving expectant patients in this uniquely complex market access environment.

Pharmaceutical Executive
From the Editor

April 22, 2015

Learnings gleaned from our annual EAB meeting, hosted this year by Dr. David Nash, Dean of the Thomas Jefferson University School of Population Health.

Pharmaceutical Executive

Although the strategic hurdles of biosimilars market entry are not new, the task of imitating substantially more complex molecular entities offers up a host of new operational questions for pharma.

Pharmaceutical Executive

Pharm Exec profiles the journey of Healthcare Businesswomen’s Association 2015 Woman of the Year, Denice Torres, whose career demonstrates that doing right starts with finding-and being-yourself.

Pharmaceutical Executive

The looming shift to cross-border compliance in Europe puts the spotlight on the evolving role of chief compliance officers.

Pharmaceutical Executive
Columns

April 14, 2015

Is it time to view cell therapy companies differently on Wall Street-even distinct from biotech?

Pharmaceutical Executive

Making sense of the new cost-containment model and value-for-money conundrums like those in the HCV space.

Pharmaceutical Executive

FDA is under pressure to moderate oversight of pharma advertising and promotion.

Pharmaceutical Executive

Although the strategic hurdles of biosimilars market entry are not new, the task of imitating substantially more complex molecular entities offers up a host of new operational questions for pharma.

Pharmaceutical Executive

The EU’s proposed new study on off-label prescribing is just another way of kicking the subject into the long grass.

Pharmaceutical Executive

Does patient choice matter to antitrust enforcers?

Pharmaceutical Executive
Special Sponsored Section

April 01, 2015

Energy reform may be stealing the headlines in Mexico, but a rising regulatory authority, the beginnings of healthcare reform, and cost-competitive manufacturing are fueling future growth in the country’s pharma industry-for domestic and global players alike.